Last reviewed · How we verify
fluticasone/salmeterol, tiotropium
This combination inhaler delivers a corticosteroid (fluticasone) to reduce airway inflammation and a long-acting beta-2 agonist (salmeterol) to dilate airways, plus a long-acting muscarinic antagonist (tiotropium) for sustained bronchodilation.
This combination inhaler delivers a corticosteroid (fluticasone) to reduce airway inflammation and a long-acting beta-2 agonist (salmeterol) to dilate airways, plus a long-acting muscarinic antagonist (tiotropium) for sustained bronchodilation. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).
At a glance
| Generic name | fluticasone/salmeterol, tiotropium |
|---|---|
| Also known as | seretide evohaler 250, spiriva respimat |
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Drug class | Combination inhaler: corticosteroid + long-acting beta-2 agonist + long-acting muscarinic antagonist |
| Target | Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol); M3 muscarinic receptor (tiotropium) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is an inhaled corticosteroid that suppresses airway inflammation by binding glucocorticoid receptors. Salmeterol is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors on airway smooth muscle to cause bronchodilation. Tiotropium is a long-acting muscarinic antagonist (anticholinergic) that blocks M3 receptors on airway smooth muscle, providing additional sustained bronchodilation and reducing mucus secretion.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma (maintenance therapy)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
- Dry mouth
Key clinical trials
- Asthma Research in Children and Adolescents
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
- Replication of the INSPIRE Trial in Healthcare Claims Data
- Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients (EARLY_PHASE1)
- Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: